NSAIDs are potentially drugs that inhibit the progression of radiology in central spina bna bna bnabitis.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the drug of choice for the treatment of patients with spina blingitis (SpA).
in recent years, biologics, including tumor necrotic factor (TNF) inhibitors and lecytocyte mesotonin-17 (IL-17) inhibitors, have become new treatment options.
, however, there is no clear treatment strategy to prevent ligament damage.
studies of patients with severe spina bna bna b onsexuality (AS) have shown that NSAIDs have a potential role in preventing radiological progress, but two randomized controlled trials have come to different conclusions.
more broadly, it remains to be seen whether the currently available SpA drug will delay spinal X-ray progression.
article reviews clinical studies related to NSAIDs and biological agents delaying the progression of SpA radiology, as well as genetic, animal, and clinical evidence of nsaIDs' effects on bone formation, and looks ahead to future research.
SpA and New Bone Formation Central Spinal Joint Disease (SpA) is a chronic inflammatory spinal disease with an adult prevalence rate of 0.9-1.4%, representing the disease as strong scolitis (AS).
in SpA, NSAIDs are a first-line treatment, even though biologics such as TNF inhibitors and IL-17 inhibitors have become new treatment options.
in the relief of short-term symptoms, the use of NSAIDs compliance rate is high, often used in a joint with biological agents.
conclusions are not consistent as to whether NSAIDs can slow the radiological progression of SpA.
spA patients may experience new bone formation features such as a strong shin joint, ligament bone, or even spinal fusion.
new bone formation can significantly reduce spinal activity and function, bringing a greater burden of disease to patients, so reducing new bone formation is one of the important goals of SpA treatment.
In clinical studies, the radiological progression of cervical and lumbar X-rays was semi-quantitatively evaluated using the modified Stoke strong-straight spinal scoring system (modified stoke ankylosing spondylitis spine score, mSASSS), with a score increase of 2 points considered radiological progression.
that 20 percent of patients had radiological advances over a two-year follow-up period.
But the consistency of mSASSS evaluations is generally low and less sensitive to disease progression, requiring 100 people per group to detect significant differences between the two groups in a two-year randomized controlled trial.
available evidence does not show that TNF inhibitors or IL-17 inhibitors can significantly delay radiological progression.
dose effects of biologics on delayed radiological progression were not observed among patients treated with different doses of TNF inhibitors or IL-17 inhibitors.
There are other studies comparing the effects of the use of biological agents on radiological progression, and most studies of TNF inhibitors have failed to find statistically significant effects, but two observational studies that included more than 300 people have shown that TNF inhibitors may reduce radiological progress by 50%.
il-17 inhibitors, Sukin monoantigen failed to significantly delay radiological progress compared to NSAIDs, and a team study compared sukin monoantigen (168 people) to treatment with bichlorofenic acid (69 people) 2 years of radiological progression in AS patients, using the ratio of patients without radiological progression (mSASS ≤ 0) as the endpoint indicator, found that the Sukin monoantial group appeared to have a higher but not significant proportion of radiological progression (60.7% vs. 52.2 per cent; P . . . 0.2430), but the mSASSS evaluation in the study was less consistent and there were more smokers in the bichlorofenic acid queue.
table 1 biologics and AS patient radiology progression related to the study of NSAAIDs and SpA new bone formation for NSAIDs, observational studies support its delay in radiological progression, German SpA queue accepts high doses of NSAI The two-year radiology progress rate for people with DS (NSAIDs ≥ 50) was significantly lower than for those who did not receive high doses of NSAIDs, and nsaIDs' delay in radiological progress was independent of disease activity.
but the results of the two existing randomized controlled trials were reversed.
study, from the Netherlands, which included 215 AS patients and resulted in continuous or on-demand use of COX-2 selective inhibitor celexib 100 mg/day for 2 years, found that the average number of mSASSS in the continuous use group was significantly lower than in the on-demand use group (0.4 ± 1.7 vs. 1.5 ± 2.5, p s 0.002).
another study, from Germany, included 167 AS patients who had been taking bichlorofenic acid continuously or on demand for 150 mg/day for 2 years, and in this study, the progress of continuous use of mSASSS was even higher in value.
two studies suggest that only COX-2 selective inhibitors may delay radiology progression.
a new clinical trial will examine the effects of TNF inhibitors and celexib on radiological progression in AS patients (ClinicalTrials.gov:NCT02758782) Table 2 NSAIDs and AS Patient Radiology Advances, providing evidence for NSAIDs to inhibit new bone formation.
NSAIDs are inhibitors for COX-1 and COX-2.
genetic analysis showed that the single nucleotide polymorphism (SNP) of the COX-1 encoded gene (PTGS1) was associated with reduced radiological damage.
in-body tests have shown that COX-2 can be produced under the stimulation of inflammatory factors and mechanical stress, and promote PGE2 production and participate in bone metabolism.
animal tests showed that THE COX-2 knock-out mice had slower fracture healing and reduced hetero-osteolysis, and this conclusion is consistent with the conclusion of clinical meta-analysis.
1 prosthyroid path in bone metabolism.
COX: Epoxyase, PGH2/PGG2/PGE2: Prosthetin H2/G2/E2, EP: Prosthetin-like subject E Conclusions and Prospects Although current treatments can effectively alleviate symptoms in SpA patients, treatments that delay radiological progress are still unclear.
observational studies suggest that nonsteroidal anti-inflammatory drugs may slow new bone formation in AS patients;
genetics and animal studies have shown that nonsteroidal anti-inflammatory drugs have a potential effect on bone formation.
future studies could use more sensitive 3D imaging techniques such as CT to assess radiological advances, and could also consider limiting experimental populations to those with high-risk radiology advances to reach more efficient conclusions.
, new factors that may be relevant to radiological progress, such as PTH and vitamin D levels found in recent years, should continue to be included to make the analysis more accurate and reliable.
3 X-rays compared to CT-rated SpA references: Wang R., Bathon J.M., and Ward M.M. Nonsteroidal Antiinflammatory Drugs as Potential Disease-Modifying Medications in Axial Spondyloarthritis. Arthritis and Rheumatology. 72 (4): pp 518-528. Translated and interpreted by: Li Chen Lichen, Chief Physician, M.D., Chinese Medicine, Beijing Concord Hospital; Visiting Scholar, Harvard Medical School, USA; member of graPPA), member of the International Psoriasis and Psoriasis Arthritis (GRAPPA), establishment of the world's largest SAPHO syndrome cohort study - 1120 patients; currently published or received SAPHO-related SCI article 39 articles, cumulative impact factor 124.4 27 (including ARD and JAMA Dermatology; reviewers of several English-language journals such as Modern Rheumatology, International Journal of Rheumatology; 2017 ACR Annual Meeting, 2018 EULAR Wall Report; Chair of 1 Project on the National Natural Science Foundation; Completion of 1 Project for Health Development Research in the Capital; Collaboration with Innovation Team Project's own Inflammation Sub-Group PI; participation in national research and development programs for rare diseases. Chaired a number of researcher-initiated clinical registration studies, completed the "Clinical Trial: NCT 02544659) for the treatment of SAPHO syndrome intravenous applications", SAPHO syndrome cohort research and multi-technology collaboration won the Concord Hospital Medical Outcomes 2nd Prize, and 2018 Concord Future Star 3rd Prize.
Li Chen Source: Medical Road Hengrui Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medical, and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Met Medical".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.